All In Biotech

Drug Trial Radar · NCT06556186

Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma

Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Peking Union Medical College Hospital; West China Hospital; First Affiliated Hospital of Wenzhou Medical University; Ningbo Medical Center Lihuili Hospital
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators carried out a multi-center comparative study, involving hospitals including the Second Affiliated Hospital of Zhejiang University School of Medicine, Peking Union Medical College Hospital, West China Hospital, Wenzhou First Hospital, and Li Huili Hospital. This study aimed to compare the efficacy of medication and surgery for specific subtypes of microadenomas and clearly defined macroadenomas (Knosp grades 0-2), in order to determine which is more effective and which has fewer benefits, thereby enhancing the evidence base.

Conditions

  • Pituitary Tumor

Interventions

  • Transnasal transsphenoidal pituitary lesion resection under neuroendoscopyProcedure

    Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy

  • Bromocriptin 2.5mg, 2-3 times a dayDrug

    Bromocriptin 2.5mg, 2-3 times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pituitary hormone levelsTime frame: At 1, 3, 6, 9 and 12 months postoperatively
  2. pituitary MRITime frame: At 1,6 and 12 months postoperatively

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.